Michael C Dugan

Company: Biocept

Job title: Senior Vice President, Chief Medical Officer & Medical Director

Seminars:

A Novel Cerebral Spinal Fluid (CSF) Assay for Assessing HER2 Genetic Heterogeneity and Monitoring Treatment Response in Patients with Leptomeningeal Metastases (LM) 2:30 pm

CNSide is a novel cerebral spinal fluid (CSF)-based assay that uses a combination of cell-based and cell-free DNA (cfDNA) analysis to evaluate patients with CNS metastasis Aids physicians in following: Identification of tumor cells in CSF Characterization of tumor heterogeneity in biomarker targets Monitoring of therapy response with serial quantitative tumor cell counts Can be…Read more

day: Day One